Serina Therapeutics, Inc.

https://serinatx.com

Serina Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology. The company's core business revolves around its proprietary POZ Platform™ (poly(2-oxazoline) polymer technology), which aims to optimize drug delivery by enabling precise, controlled, and sustained drug exposure. This technology is designed to unlock the full potential of proven small molecule therapeutics, improving their performance in the body by extending delivery intervals, reducing side effects, and enhancing patient experience.

Serina Therapeutics develops a pipeline of drug candidates primarily targeting neurological diseases and pain. Its lead product candidate, SER-252 (POZ-apomorphine), is in a Phase 1b registrational trial for the treatment of advanced Parkinson's disease. The company is also developing SER-270 for Tardive Dyskinesia, which is anticipated to enter IND enabling studies, and SER-214 for early Parkinson's and Restless Leg Syndrome. Beyond these, Serina's POZ Platform™ is applied to POZ-lipids for lipid nanoparticle delivered RNA vaccines and is explored for applications in RNA medicines, cancer immunotherapy, and gene therapy through partnerships.

In recent news, Serina Therapeutics announced the FDA clearance of its IND application for SER-252 in January 2026, followed by the enrollment of the first patient in its Phase 1b registrational trial for advanced Parkinson's disease in February 2026. The company secured up to $30 million in private placement financing in March 2026 to advance this trial. In April 2026, the NYSE American accepted Serina's plan for continued listing compliance. Steve Ledger serves as the Chief Executive Officer, and Srini Tenjarla, Ph.D., was promoted to Chief Technology Officer in April 2026.

Latest updates

Serina Therapeutics Presents Data on PEG-Alternative Lipid Nanoparticles

Event summary

  • Serina Therapeutics' Chief Development Officer, Randall Moreadith, presented data at the 5th LNP Formulation & Process Development Summit on April 7, 2026.
  • The presentation focused on Serina’s POZ Platform, which aims to replace PEG-lipids in lipid nanoparticle (LNP) formulations.
  • Data showed Serina’s POZ-lipid did not elicit an antibody response in rats, addressing a key safety concern with current PEG-lipid formulations.
  • Serina is also developing novel ionizable POZ lipids to replace existing ionizable lipids, another area of LNP safety concern.

The big picture

The LNP field has faced increasing scrutiny regarding safety concerns, particularly around PEG immunogenicity and ionizable lipid toxicity. Serina’s POZ Platform represents a potential solution to these issues, aiming to create safer and more versatile LNP-based therapeutics. The company’s progress could significantly impact the development of RNA-based therapies and ADCs, a market currently valued at billions of dollars.

What we're watching

Clinical Translation
The rat data is encouraging, but the efficacy and safety of the POZ-lipid platform will need to be validated in human clinical trials to determine its true potential.
Regulatory Scrutiny
The FDA and other regulatory bodies are increasingly focused on LNP safety, so Serina’s progress in addressing PEG immunogenicity will be closely examined during future regulatory submissions.
Commercial Adoption
The success of Serina’s platform hinges on its ability to be broadly adopted across various oligonucleotide payloads and therapeutic applications, potentially impacting the existing LNP market.

Serina Therapeutics Secures NYSE American Compliance Extension

Event summary

  • Serina Therapeutics received a notice on January 9, 2026, indicating non-compliance with NYSE American listing standards due to low stockholders' equity ($1.6 million) and recent losses.
  • The company has submitted a business plan accepted by NYSE American to regain compliance.
  • Serina now has until July 9, 2027, to meet the continued listing standards.
  • During this period, Serina will be subject to quarterly monitoring by NYSE American.
  • Failure to comply could result in suspension and delisting.

The big picture

Serina's situation highlights the challenges faced by clinical-stage biotech companies with limited capital and ongoing development expenses. The NYSE American's acceptance of the compliance plan provides a temporary reprieve, but the company's long-term viability depends on demonstrating tangible progress in its drug development pipeline and improving its financial performance. This situation is increasingly common as smaller biotechs struggle to maintain listing requirements amidst volatile market conditions and high R&D costs.

What we're watching

Execution Risk
The success of Serina's compliance plan hinges on the progress of the SER-252 clinical program; delays or setbacks could jeopardize their ability to meet the July 2027 deadline.
Financial Resources
Given the current low equity and history of losses, Serina will likely need to secure additional funding to sustain operations and meet listing requirements, potentially diluting existing shareholders.
Governance Dynamics
NYSE American's quarterly monitoring will likely increase scrutiny of Serina's management and financial reporting, potentially impacting operational flexibility and investor confidence.

Serina Therapeutics Boosts Balance Sheet, Advances Parkinson's Trial

Event summary

  • Serina Therapeutics received FDA Investigational New Drug (IND) clearance for SER-252 in January 2026 and initiated a Phase 1b trial in February 2026.
  • The company secured a private placement financing of up to $30 million, receiving $16 million as of March 23, 2026.
  • Serina has sold $12.9 million worth of common stock through an At-the-Market (ATM) equity program.
  • The company reported a net loss of $19.4 million for the full year ended December 31, 2025, compared to $11.1 million in 2024.

The big picture

Serina's financing round, led by Greg Bailey, signals renewed investor confidence in the POZ platform and its potential to optimize existing drugs for neurological disorders. The company's reliance on ATM offerings and convertible notes, while providing near-term funding, also introduces dilution risk and warrants close monitoring of capital structure. The Phase 1b trial for SER-252 represents a pivotal moment, as positive data could significantly de-risk the program and attract further investment.

What we're watching

Clinical Efficacy
The Phase 1b trial results for SER-252 will be critical in determining the drug's potential to address motor complications in Parkinson's disease, and the data will heavily influence future development and investment.
Financing Sustainability
Whether Serina can successfully deploy the new capital and maintain a reasonable burn rate will be key to sustaining operations through the ongoing clinical trials and beyond.
Platform Expansion
The success of SER-252 will likely dictate the pace of expansion of Serina’s POZ platform into other therapeutic areas and potential out-licensing opportunities.

Serina Therapeutics to Present at Roth Conference, Highlighting POZ Platform

Event summary

  • Serina Therapeutics CEO Steve Ledger will present at the 38th Annual Roth Conference on March 24, 2026.
  • The fireside chat will be webcast live and archived for 90 days.
  • Serina is developing its proprietary POZ Platform™ for drug optimization.
  • Serina has a non-exclusive license agreement with Pfizer for use of its POZ polymer technology in lipid nanoparticle drug delivery.

The big picture

Serina Therapeutics’ POZ Platform represents a novel approach to drug delivery, aiming to improve the efficacy and safety of existing therapeutics. The company’s reliance on out-licensing and partnerships, as evidenced by the Pfizer agreement, suggests a strategy of leveraging its technology rather than solely relying on internal drug development. The Roth Conference presentation provides a key opportunity to assess the progress and potential of this strategy, particularly given the challenges inherent in developing treatments for neurological diseases.

What we're watching

Clinical Progress
The presentation will likely detail progress on SER-252, and investor sentiment will hinge on any updates regarding clinical trial enrollment and data readouts, given the narrow therapeutic window of apomorphine.
Partnership Impact
The success of the Pfizer partnership will be a key indicator of the broader applicability of the POZ platform, and further out-licensing deals could significantly impact Serina’s revenue potential.
Financial Stability
Given the cautionary language regarding Serina’s ability to continue as a going concern, investors should monitor the company’s cash runway and ability to secure additional funding to support its clinical programs.

Serina Therapeutics Lands $30 Million Private Placement, Bolsters Parkinson's Trial Funding

Event summary

  • Serina Therapeutics secured a private placement of up to $30 million, with a first tranche of $15 million expected to close on March 20, 2026.
  • The financing includes pre-funded warrants potentially adding up to $33.3 million, extending the company’s runway into 2H 2027.
  • The proceeds will directly fund an ongoing registrational study for SER-252, a treatment for advanced Parkinson’s disease, utilizing a 505(b)(2) regulatory pathway.
  • Greg Bailey, M.D., a current Board Director, will assume the role of Co-Chairman of the Board.

The big picture

This financing underscores the continued investor interest in novel therapies for Parkinson’s disease, a market with significant unmet need. The structure, including the warrant coverage and milestone-gated funding, suggests a degree of risk aversion from investors, tying capital deployment to clinical progress. Greg Bailey’s involvement, given his track record with successful biotech exits like Biohaven and Medivation, signals a belief in Serina’s potential, but also introduces a focus on accelerating value creation.

What we're watching

Clinical Execution
The success of the registrational trial, particularly the topline results expected in 1H 2027, will be critical in validating SER-252's efficacy and driving future valuation.
Warrant Exercise
The exercise of the pre-funded warrants, contingent on share price performance and trial milestones, will significantly impact Serina’s cash position and potentially dilute existing shareholders.
Regulatory Pathway
How Serina navigates the 505(b)(2) regulatory pathway and FDA feedback will determine the speed and cost of potential market approval for SER-252.

Serina Therapeutics Begins Phase 1b Trial for Parkinson's Drug, Eyes Expedited Approval

Event summary

  • Serina Therapeutics initiated a Phase 1b registrational clinical trial for SER-252, a treatment for advanced Parkinson’s disease.
  • The trial aims to evaluate SER-252’s safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with inadequate symptom control.
  • A Safety Monitoring Committee will review data from Cohort 1, with advancement to Cohort 2 anticipated in Q3 2026.
  • The trial leverages Serina’s proprietary POZ Platform™ drug optimization technology and is aligned with a 505(b)(2) NDA pathway.
  • Clinical sites include Australia, where Serina has established relationships with investigators.

The big picture

Serina's approach of optimizing existing drugs with its POZ Platform™ represents a capital-efficient strategy in a sector increasingly focused on precision medicine. The Phase 1b trial’s registrational designation suggests a potential for accelerated approval, but also increases scrutiny. The company’s reliance on partnerships, particularly with Neuroscience Trials Australia and Pfizer, will be crucial for execution and future platform expansion.

What we're watching

Regulatory Pathway
The FDA’s acceptance of the Phase 1b trial as registrational significantly streamlines the approval process, but hinges on successful data readouts and continued alignment with the 505(b)(2) pathway.
Clinical Execution
The trial’s success depends on efficient patient enrollment and data collection across global sites, particularly in Australia, where Serina has established key partnerships.
Platform Risk
While the POZ Platform™ offers potential for broad application, Serina’s valuation is tied to the success of SER-252; failure to demonstrate efficacy or safety could impact the platform’s perceived value.

Serina Therapeutics Enrolls First Patient in Registrational Trial for Parkinson's Therapy

Event summary

  • Serina Therapeutics initiated a Phase 1b registrational trial for SER-252, its apomorphine therapy for advanced Parkinson's disease.
  • The first patient was enrolled in the trial, which is taking place in Australia.
  • The trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252.
  • Serina is proceeding on track for first patient dosing in Q1 2026, as previously indicated.
  • The trial is designed to leverage a 505(b)(2) NDA pathway with FDA alignment.

The big picture

Serina's advancement of SER-252 represents a focused effort to address the significant unmet need for improved therapies in advanced Parkinson's disease, a market with a growing patient population and substantial potential for innovation. The company’s reliance on the 505(b)(2) pathway suggests a strategy to leverage existing drug data, potentially accelerating approval timelines, but also increasing regulatory scrutiny. The success of SER-252 hinges on the POZ Platform's ability to deliver a clinically meaningful benefit while mitigating the limitations of existing apomorphine therapies.

What we're watching

Enrollment Pace
The speed of patient enrollment across trial sites will be a key indicator of Serina's operational effectiveness and ability to meet trial timelines, particularly given the reliance on patient advocacy groups.
Regulatory Scrutiny
The FDA's ongoing assessment of Serina's 505(b)(2) development strategy and the data generated from this trial will dictate the path to potential commercialization and influence future development decisions.
Clinical Efficacy
Early efficacy data from the Phase 1b trial will be critical in validating the POZ Platform's ability to improve apomorphine delivery and reduce levodopa-related motor complications in Parkinson's patients.

Serina Therapeutics Clears FDA Path for Parkinson's Therapy

Event summary

  • Serina Therapeutics received FDA clearance for an Investigational New Drug (IND) application for SER-252, a therapy targeting advanced Parkinson’s disease.
  • The clearance enables Serina to proceed with a Phase 1b registrational clinical study.
  • Serina intends to pursue a 505(b)(2) NDA pathway for SER-252, indicating a reliance on existing data.
  • The company has previously engaged in regulatory interactions with the FDA regarding the SER-252 program, receiving feedback on trial design.

The big picture

The clearance represents a significant step for Serina, positioning it to address a substantial unmet need in advanced Parkinson’s disease, a market with a growing aging population. The 505(b)(2) pathway suggests a strategy to accelerate approval by leveraging existing data, but also introduces reliance on prior research. The POZ platform's versatility, as evidenced by the Pfizer partnership, could unlock broader commercial opportunities if successfully applied to other therapeutic areas.

What we're watching

Clinical Execution
The success of the Phase 1b registrational study will be critical, as it will generate the initial clinical data underpinning Serina's regulatory strategy and commercial prospects.
Regulatory Risk
While the FDA has indicated alignment on a 505(b)(2) pathway, potential shifts in regulatory interpretation or new data could still impact the approval timeline and requirements.
Platform Leverage
The extent to which Serina can leverage its POZ platform across additional drug candidates and partnerships will determine the long-term value creation potential beyond SER-252.

Serina Therapeutics Faces NYSE Delisting Threat Amid Equity Deficit

Event summary

  • Serina Therapeutics received a NYSE deficiency notification due to falling below continued listing criteria.
  • The company's stockholders' equity as of September 30, 2025, was reported at $1.6 million.
  • Serina has experienced losses in three of the last four fiscal years.
  • The company must submit a plan to regain compliance by February 8, 2026, with a cure period ending July 9, 2027.

The big picture

This notification highlights the precarious financial position of many clinical-stage biotech companies, particularly those reliant on external funding and facing lengthy development timelines. The NYSE's stricter listing requirements are putting increased pressure on smaller, unprofitable companies to demonstrate a path to profitability. Serina's reliance on its proprietary POZ platform and a single lead candidate, SER-252, amplifies its risk profile and underscores the importance of successful clinical trial outcomes.

What we're watching

Plan Acceptance
The NYSE's acceptance of Serina's remediation plan will be critical; rejection would trigger delisting proceedings and significantly impact investor confidence.
Financial Performance
Whether Serina can achieve profitability within the 18-month cure period will determine its long-term viability and ability to maintain its listing.
Partnership Leverage
The extent to which Serina can leverage its partnership with Pfizer to generate revenue or secure additional funding will be a key indicator of its ability to address its financial challenges.
CID: 244